Agnogenic myeloid metaplasia with myelofibrosis: Indolent myeloproliferative syndrome (usually has splenomegaly)
Acute myelofibrosis (usually no splenomegaly)
IMAGING
General Features
Imaging Recommendations
Radiographic Findings
MR Findings
DIFFERENTIAL DIAGNOSIS
PATHOLOGY
General Features
Microscopic Features
CLINICAL ISSUES
Presentation
Demographics
Natural History & Prognosis
Treatment
DIAGNOSTIC CHECKLIST
Consider
Selected References
Kröger N et al: Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis. Blood. 125(21):3347-50, 2015
Markiewicz M et al: Safety and outcome of allogeneic stem cell transplantation in myelofibrosis. Eur J Haematol. ePub, 2015
Palandri F et al: Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia. 29(6):1344-9, 2015
Ihde LL et al: Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis. Radiographics. 31(7):1865-82, 2011
Kvasnicka HM et al: Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol. 85(1):62-9, 2010
Etienne A et al: Myelofibrosis-associated lymphoproliferative disease: retrospective study of 16 cases and literature review. Adv Hematol. 2009:179847, 2009
Mesa RA et al: Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 14(3):471-9, 2009
Orazi A et al: Myelodysplastic syndromes. Am J Clin Pathol. 132(2):290-305, 2009
Plo I et al: Molecular and genetic bases of myeloproliferative disorders: questions and perspectives. Clin Lymphoma Myeloma. 9 Suppl 3:S329-39, 2009
Agnogenic myeloid metaplasia with myelofibrosis: Indolent myeloproliferative syndrome (usually has splenomegaly)
Acute myelofibrosis (usually no splenomegaly)
IMAGING
General Features
Imaging Recommendations
Radiographic Findings
MR Findings
DIFFERENTIAL DIAGNOSIS
PATHOLOGY
General Features
Microscopic Features
CLINICAL ISSUES
Presentation
Demographics
Natural History & Prognosis
Treatment
DIAGNOSTIC CHECKLIST
Consider
Selected References
Kröger N et al: Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis. Blood. 125(21):3347-50, 2015
Markiewicz M et al: Safety and outcome of allogeneic stem cell transplantation in myelofibrosis. Eur J Haematol. ePub, 2015
Palandri F et al: Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia. 29(6):1344-9, 2015
Ihde LL et al: Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis. Radiographics. 31(7):1865-82, 2011
Kvasnicka HM et al: Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol. 85(1):62-9, 2010
Etienne A et al: Myelofibrosis-associated lymphoproliferative disease: retrospective study of 16 cases and literature review. Adv Hematol. 2009:179847, 2009
Mesa RA et al: Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 14(3):471-9, 2009
Orazi A et al: Myelodysplastic syndromes. Am J Clin Pathol. 132(2):290-305, 2009
Plo I et al: Molecular and genetic bases of myeloproliferative disorders: questions and perspectives. Clin Lymphoma Myeloma. 9 Suppl 3:S329-39, 2009
STATdx includes over 200,000 searchable images, including x-ray, CT, MR and ultrasound images. To access all images, please log in or subscribe.